Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Ewa Jaworowska is active.

Publication


Featured researches published by Ewa Jaworowska.


Carcinogenesis | 2008

Constitutional CHEK2 mutations are associated with a decreased risk of lung and laryngeal cancers

Cezary Cybulski; Bartłomiej Masojć; Dorota Oszutowska; Ewa Jaworowska; Tomasz Grodzki; Piotr Waloszczyk; Piotr Serwatowski; Juliusz Pankowski; Tomasz Huzarski; Tomasz Byrski; Bohdan Górski; Anna Jakubowska; Tadeusz Dębniak; Dominika Wokołorczyk; Jacek Gronwald; Czesława Tarnowska; Pablo Serrano-Fernández; Jan Lubinski; Steven A. Narod

Mutations in the CHEK2 gene have been associated with increased risks of breast, prostate and colon cancer. In contrast, a previous report suggests that individuals with the I157T missense variant of the CHEK2 gene might be at decreased risk of lung cancer and upper aero-digestive cancers. To confirm this hypothesis, we genotyped 895 cases of lung cancer, 430 cases of laryngeal cancer and 6391 controls from Poland for four founder alleles in the CHEK2 gene, each of which has been associated with an increased risk of cancer at several sites. The presence of a CHEK2 mutation was protective against both lung cancer [odds ratio (OR) = 0.3; 95% confidence interval (CI) 0.2-0.5; P = 3 x 10(-8)] and laryngeal cancer (OR = 0.6; 95% CI 0.3-0.99; P = 0.05). The basis of the protective effect is unknown, but may relate to the reduced viability of lung cancer cells with a CHEK2 mutation. Lung cancers frequently possess other defects in genes in the DNA damage response pathway (e.g. p53 mutations) and have a high level of genotoxic DNA damage induced by tobacco smoke. We speculate that lung cancer cells with impaired CHEK2 function undergo increased rates of cell death.


PLOS ONE | 2013

A Low Selenium Level Is Associated with Lung and Laryngeal Cancers

K Jaworska; Satish Gupta; Katarzyna Durda; Magdalena Muszyńska; Grzegorz Sukiennicki; Ewa Jaworowska; Tomasz Grodzki; Mieczysław Sulikowski; Piotr Woloszczyk; Janusz Wójcik; J. Lubinski; Cezary Cybulski; Tadeusz Dębniak; Marcin Lener; Antoni W. Morawski; Karol Krzystolik; Steven A. Narod; Ping Sun; Jan Lubinski; Anna Jakubowska

Purpose It has been suggested that selenium deficiency is a risk factor for several cancer types. We conducted a case-control study in Szczecin, a region of northwestern Poland, on 95 cases of lung cancer, 113 cases of laryngeal cancer and corresponding healthy controls. Methods We measured the serum level of selenium and established genotypes for four variants in four selenoprotein genes (GPX1, GPX4, TXNRD2 and SEP15). Selenium levels in the cases were measured after diagnosis but before treatment. We calculated the odds of being diagnosed with lung or laryngeal cancer, conditional on selenium level and genotype. Results Among lung cancer cases, the mean selenium level was 63.2 µg/l, compared to a mean level of 74.6 µg/l for their matched controls (p<0.0001). Among laryngeal cancer cases, the mean selenium level was 64.8 µg/l, compared to a mean level of 77.1 µg/l for their matched controls (p<0.0001). Compared to a serum selenium value below 60 µg/l, a selenium level above 80 µg/l was associated with an odds ratio of 0.10 (95% CI 0.03 to 0.34; p = 0.0002) for lung cancer and 0.23 (95% CI 0. 09 to 0.56; p = 0.001) for laryngeal cancer. In analysis of four selenoprotein genes we found a modest evidence of association of genetic variant in GPX1 with the risk of lung and laryngeal cancers. Conclusion A selenium level below 60 µg/l is associated with a high risk of both lung and laryngeal cancer.


PLOS ONE | 2011

Smoking related cancers and loci at chromosomes 15q25, 5p15, 6p22.1 and 6p21.33 in the Polish population.

Ewa Jaworowska; Joanna Trubicka; Marcin Lener; Bartłomiej Masojć; Elżbieta Złowocka-Perłowska; James D. McKay; Helene Renard; Dorota Oszutowska; Dominika Wokołorczyk; J. Lubinski; Tomasz Grodzki; Piotr Serwatowski; Katarzyna Nej-Wołosiak; Aleksandra Tołoczko-Grabarek; Andrzej Sikorski; Marcin Słojewski; Anna Jakubowska; Cezary Cybulski; Jan Lubinski; Rodney J. Scott

Genetic factors associated with the risk of smoking related cancers have until recently remained elusive. Since the publication of a genome-wide association study (GWAS) on lung cancer new genetic loci have been identified that appear to be associated with disease risk. In this replication study we genotyped 14 single nucleotide polymorphisms (SNPs) located at the 5p12.3-p15.33, 6p21.3-p22.1, 6q23-q27 and 15q25.1 loci in 874 lung, 450 bladder, 418 laryngeal cancer cases and cancer-free controls, matched by year of birth and sex to the cases. Our results revealed that loci in the chromosome region 15q25.1 (rs16969968[A], rs8034191[G]) and 5p15 (rs402710[T]) are associated with lung cancer risk in the Polish population (smoking status adjusted OR = 1.45, 1.35, 0.77; p≤0.0001, 0.0005, 0.002; 95%CI 1.23–1.72, 1.14–1.59, 0.66–0.91 respectively). None of the other regions analyzed herein were implicated in the risk of lung, bladder or laryngeal cancer. This study supports previous findings on lung cancer but fails to show association of SNPs located in 15q25.1 and 5p15 region with other smoking related cancers like bladder and laryngeal cancer.


International Journal of Cancer | 2006

CDKN2A common variant and multi‐organ cancer risk—a population‐based study

Tadeusz Dębniak; Rodney J. Scott; Tomasz Huzarski; Tomasz Byrski; Andrzej Rozmiarek; Bogusław Dębniak; Bohdan Górski; Cezary Cybulski; Krzysztof Mędrek; Marek Mierzejewski; Bartłomiej Masojć; Joanna Matyjasik; Elżbieta Złowocka; Urszula Teodorczyk; Marcin Lener; Ewa Kłujszo-Grabowska; Katarzyna Nej-Wołosiak; Ewa Jaworowska; Dorota Oszutowska; Anna Szymańska; Jolanta Szymańska; Jennifer Castaneda; Thierry van de Wetering; Janina Suchy; Grzegorz Kurzawski; Oleg Oszurek; Steven A. Narod; Jan Lubinski

The population frequencies of the CDKN2A common variants remain undetermined. In Poland, there is a common variant of the CDKN2A: an alanine to threonine substitution (A148T), which has been detected in other populations. We have recently showed that it is significantly overrepresented among Polish melanoma patients when compared to general population. Herein, we ascertained the prevalence of the A148T variant in 3,583 unselected cancer cases and 3,000 random control subjects from the same Polish population. We evaluated eleven different malignancies, representing the majority of all common cancer sites. Positive association with A148T variant was observed for lung cancer (OR, 2.0; p = 0.0052). A similar trend, although nonsignificant after the Bonferroni correction, was observed for colorectal cancer (OR, 1.5; p = 0.5499). These results suggest that A148T variant may be associated with a multi‐organ cancer risk in the Polish population.


Journal of the National Cancer Institute | 2015

A Rare Truncating BRCA2 Variant and Genetic Susceptibility to Upper Aerodigestive Tract Cancer

Manon Delahaye-Sourdeix; Devasena Anantharaman; Maria Timofeeva; Valerie Gaborieau; Amelie Chabrier; Maxime P. Vallée; Pagona Lagiou; Ivana Holcatova; Lorenzo Richiardi; Kristina Kjaerheim; Antonio Agudo; Xavier Castellsagué; Tatiana V. MacFarlane; Luigi Barzan; Cristina Canova; Nalin S. Thakker; David I. Conway; Ariana Znaor; Claire M. Healy; Wolfgang Ahrens; David Zaridze; Neonilia Szeszenia-Dabrowska; Jolanta Lissowska; Eleonora Fabianova; Ioan Nicolae Mates; Vladimir Bencko; Lenka Foretova; Vladimir Janout; Maria Paula Curado; Sergio Koifman

Deleterious BRCA2 genetic variants markedly increase risk of developing breast cancer. A rare truncating BRCA2 genetic variant, rs11571833 (K3326X), has been associated with a 2.5-fold risk of lung squamous cell carcinoma but only a modest 26% increase in breast cancer risk. We analyzed the association between BRCA2 SNP rs11571833 and upper aerodigestive tract (UADT) cancer risk with multivariable unconditional logistic regression adjusted by sex and combinations of study and country for 5942 UADT squamous cell carcinoma case patients and 8086 control patients from nine different studies. All statistical tests were two-sided. rs11571833 was associated with UADT cancers (odds ratio = 2.53, 95% confidence interval = 1.89 to 3.38, P = 3x10-10) and was present in European, Latin American, and Indian populations but extremely rare in Japanese populations. The association appeared more apparent in smokers (current or former) compared with never smokers (P het = .026). A robust association between a truncating BRCA2 variant and UADT cancer risk suggests that treatment strategies orientated towards BRCA2 mutations may warrant further investigation in UADT tumors.


PLOS ONE | 2015

The 12p13.33/RAD52 locus and genetic susceptibility to squamous cell cancers of upper aerodigestive tract.

Manon Delahaye-Sourdeix; Javier Oliver; Maria Timofeeva; Valerie Gaborieau; Mattias Johansson; Amelie Chabrier; Magdalena B. Wozniak; Darren R. Brenner; Maxime P. Vallée; Devasena Anantharaman; Pagona Lagiou; Ivana Holcatova; Lorenzo Richiardi; Kristina Kjaerheim; Antonio Agudo; Xavier Castellsagué; Tatiana V. Macfarlane; Luigi Barzan; Cristina Canova; Nalin Thakker; David I. Conway; Ariana Znaor; Claire M. Healy; Wolfgang Ahrens; David Zaridze; Neonilia Szeszenia-Dabrowska; Jolanta Lissowska; Eleonora Fabianova; Ioan Nicolae Mates; Vladimir Bencko

Genetic variants located within the 12p13.33/RAD52 locus have been associated with lung squamous cell carcinoma (LUSC). Here, within 5,947 UADT cancers and 7,789 controls from 9 different studies, we found rs10849605, a common intronic variant in RAD52, to be also associated with upper aerodigestive tract (UADT) squamous cell carcinoma cases (OR = 1.09, 95% CI: 1.04–1.15, p = 6x10−4). We additionally identified rs10849605 as a RAD52 cis-eQTL inUADT(p = 1x10−3) and LUSC (p = 9x10−4) tumours, with the UADT/LUSC risk allele correlated with increased RAD52 expression levels. The 12p13.33 locus, encompassing rs10849605/RAD52, was identified as a significant somatic focal copy number amplification in UADT(n = 374, q-value = 0.075) and LUSC (n = 464, q-value = 0.007) tumors and correlated with higher RAD52 tumor expression levels (p = 6x10−48 and p = 3x10−29 in UADT and LUSC, respectively). In combination, these results implicate increased RAD52 expression in both genetic susceptibility and tumorigenesis of UADT and LUSC tumors.


PLOS ONE | 2018

Serum selenium levels and the risk of progression of laryngeal cancer

Jan Lubinski; Wojciech Marciniak; Magdalena Muszyńska; Ewa Jaworowska; Mieczysław Sulikowski; Anna Jakubowska; Katarzyna Kaczmarek; Grzegorz Sukiennicki; Michal Falco; Piotr Baszuk; Magdalena Mojsiewicz; Joanne Kotsopoulos; Ping Sun; Steven A. Narod

Background Observational studies have reported an inverse relationship between selenium status (blood or toenail) and the risk of laryngeal cancer; however, the impact of low serum selenium level on survival has not been evaluated. Methods We conducted a prospective study of 296 patients diagnosed with laryngeal cancer in Szczecin, Poland. Serum selenium was measured at diagnosis and prior to treatment. Patients were followed from the date of diagnosis to death at five years. Vital status was obtained by linkage to the Polish National Death Registry. Results The five-year survival after diagnosis was 82.0% (95% CI: 68% to 91%) for individuals in the highest quartile of serum selenium (> 66.8 μg/L) and was 28.6% (95% CI 19% to 42%) for individuals in the lowest quartile (<50.0 μg/L). In an age- and sex-adjusted analysis, the hazard ratio (HR) for death from all causes was 7.01 (95% CI 3.81 to 12.9) for patients in the lowest quartile of serum selenium, compared to those in the highest quartile. The corresponding multivariate HR was 3.07 (95% CI 1.59 to 5.94). Conclusions This study suggests that a selenium level in excess of 70 μg/L is associated with improved outcome among patients undergoing treatment for laryngeal cancer. Further studies are needed to evaluate if selenium supplementation to achieve this level might improve overall prognosis.


Medical Science Monitor | 2015

The Role of Nrf2 in Pathology of Pleomorphic Adenoma in Parotid Gland

Agnieszka Droździk; Robert Kowalczyk; Ewa Jaworowska; Elżbieta Urasińska; Mateusz Kurzawski

Background Pleomorphic adenoma (benign mixed tumor) is one of the most common salivary gland tumors. However, the processes involved in its carcinogenesis are not well defined. This study aimed to define the contribution of Nfr2 (nuclear factor (erythroid-derived 2)-like 2) to pleomorphic adenoma pathology. The Nrf2-controlled gene system is one of the most critical cytoprotective mechanisms, providing antioxidant responses. Material/Methods The study was carried out in pleomorphic adenoma and control parotid gland tissues, investigating gene expression of NFE2L2, as well as KEAP1 (Kelch-like ECH-associated protein 1) and NQO1 (quinone oxidoreductase), at mRNA and protein (immunohistochemistry) levels. Functional evaluation of Nrf2 system in the parotid gland was evaluated in HSY cells (human parotid gland adenocarcinoma cells). Results Pleomorphic adenoma specimens showed cytoplasmic and nuclear Nfr2 expression in epithelial cells, as well as more variable lower Nrf2 level in mesenchymal cells. In the parotid gland, Nrf2 was expressed in cytoplasm of serous, mucous, and duct cells. Nuclear Nrf2 expression was predominantly seen in serous cells, whereas mucous and duct cells were mostly negative. Comparable mRNA levels of NFE2L2 and NQO1 genes and significantly higher expression of KEAP1 in pleomorphic adenoma were seen. HSY cell incubation with oltipraz demonstrated significant elevation of NFE2L2 after 24 and 48 hours of stimulation, whereas NQO1 was elevated, but significantly only after 24 hours, and KEAP1 expression remained unchanged. Conclusions Summarizing both in vitro and in vivo observations, it can be stated that Nrf2 may play a role in the pathology of pleomorphic adenoma.


Polish Journal of Surgery | 2012

Selenium as marker for cancer risk and prevention.

Marcin Lener; Katarzyna Jaworska; Magdalena Muszyńska; Grzegorz Sukiennicki; Katarzyna Durda; Satish Gupta; Elżbieta Złowocka-Perłowska; Józef Kładny; Anna Wiechowska-Kozłowska; Tomasz Grodzki; Ewa Jaworowska; J. Lubinski; Barbara Górecka-Szyld; Grażyna Wilk; Mieczysław Sulikowski; Tomasz Huzarski; Tomasz Byrski; Cezary Cybulski; Jacek Gronwald; Tadeusz Dębniak; Olgierd Ashuryk; Aleksandra Tołoczko-Grabarek; Anna Jakubowska; Antoni W. Morawski; Jan Lubinski

MARCIN LENER1*, KATARZYNA JAWORSKA1,3*, MAGDALENA MUSZYnSKA1,2, GRZEGORZ SUKIENNICKI1,2, KATARZYNA DURDA1, SATISH GUPTA1,3, ELŻBIETA ZŁOWOCKA-PERŁOWSKA1, JoZEF KŁADNY4, ANNA WIECHOWSKA-KOZŁOWSKA5, TOMASZ GRODZKI6, EWA JAWOROWSKA7, JAKUB LUBInSKI7, BARBARA GoRECKA-SZYLD8, GRAŻYNA WILK8, MIECZYSŁAW SULIKOWSKI9, TOMASZ HUZARSKI1, TOMASZ BYRSKI1, CEZARY CYBULSKI1, JACEK GRONWALD1, TADEUSZ DeBNIAK1, OLGIERD ASHURYK1, ALEKSANDRA TOŁOCZKO-GRABAREK1, ANNA JAKUBOWSKA1, ANTONI MORAWSKI10, JAN LUBInSKI1,2


Breast Cancer Research and Treatment | 2008

Familial association of laryngeal, lung, stomach and early-onset breast cancer

Ewa Jaworowska; Pablo Serrano-Fernández; Czesława Tarnowska; J. Lubinski; Marek Brzosko; Fliciński J; Bartołomej Masojc; Joanna Matyjasik; Rodney J. Scott; Steven A. Narod; Jan Lubinski

This study analyzes the incidence of different types of cancer among 2839 first-degree relatives of 760 consecutive, unselected laryngeal cancer patients, compared with the general population. A statistically significant excess was seen for other cancers of the larynx (SIR: 400), lung (SIR: 135) and stomach (SIR: 271), and early-onset breast cancer (SIR: 287). Familial laryngeal cancer may not be a single site-specific cancer syndrome.

Collaboration


Dive into the Ewa Jaworowska's collaboration.

Top Co-Authors

Avatar

J. Lubinski

Pomeranian Medical University

View shared research outputs
Top Co-Authors

Avatar

Jan Lubinski

New York Academy of Medicine

View shared research outputs
Top Co-Authors

Avatar

Anna Jakubowska

Pomeranian Medical University

View shared research outputs
Top Co-Authors

Avatar

Tadeusz Dębniak

Pomeranian Medical University

View shared research outputs
Top Co-Authors

Avatar

Cezary Cybulski

New York Academy of Medicine

View shared research outputs
Top Co-Authors

Avatar

Grzegorz Sukiennicki

Pomeranian Medical University

View shared research outputs
Top Co-Authors

Avatar

Magdalena Muszyńska

Pomeranian Medical University

View shared research outputs
Top Co-Authors

Avatar

Tomasz Grodzki

Pomeranian Medical University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Czesława Tarnowska

Pomeranian Medical University

View shared research outputs
Researchain Logo
Decentralizing Knowledge